Huntingdon Life Sciences

Huntingdon Life Sciences

Industry	Pharmaceutical industry
Founded	1951; 73 years ago (1951) in Cambridgeshire, England
Fate	Merged into Envigo (now Inotiv)
Successor	Inotiv
Headquarters	East Millstone, New Jersey
Area served	Global
Key people	Brian Cass, Former Managing Director
Services	Contract research organization
Revenue	$242 million
Operating income	$35 million
Net income	$10 million
Total assets	$171 million
Total equity	-$15 million
Number of employees	>1,600
Footnotes / references [1]

Huntingdon Life Sciences (HLS) was a contract research organisation (CRO) organized in Maryland and headquartered in East Millstone, New Jersey. It was founded in 1951 in Cambridgeshire, England. It had two laboratories in the United Kingdom and one in the United States. With over 1,600 employees, it was the largest non-clinical CRO in Europe and the third-largest non-clinical CRO in the world.^[2] In September 2015, Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR associates merged into Envigo (now Inotiv).

HLS provided contract research organization services in pre-clinical and non-clinical biological safety evaluation research. As with other major CROs operating in this business area, its major business is serving the pharmaceutical industry. However, more than a third of its business came from non-pharmaceutical sources, such as the crop protection industry which accounts for around 60% of its non-pharmaceutical business.

HLS had two facilities in the UK (Huntingdon, Cambridgeshire and Eye, Suffolk), one in the USA (East Millstone, New Jersey) and an office in Japan (Tokyo).

The company was one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates as well as on beagles. The Stop Huntingdon Animal Cruelty campaign was formed with the goal of shutting down the company due to animal rights violations.